title: Multidrug-resistant tuberculosis: this is the cost.
abstract: The costs of multidrug-resistant tuberculosis (MDR TB) reach far beyond the cost of the clinical treatment of the patient. The first impact of the discovery of MDR TB in a population is the need to recognize that all TB patients have the potential of being MDR. Public health measures to prevent the spread of MDR TB, or to control or reverse the problem where spread has already occurred, can be extremely expensive to implement. At the level of the individual patient, the second-line drugs used to treat MDR TB are more expensive, and the remaining first-line drugs will have to be used for a longer time than in drug-susceptible TB. Negative-pressure units add to the costs of treatment, as does the increased nursing intensity required. The cost to the wider economy includes lost productivity and lost tax revenue to the state as well as the cost of supporting the family if the patient is the breadwinner.
authors.affiliation: Department of Respiratory Medicine, St. Bartholomew's and Royal London Hospitals, United Kingdom. John@moore-gillon.demon.co.uk
authors.forename: J
authors.initials: J
authors.lastname: Moore-Gillon
mesh_terms: D017281:Cost of Illness; D006801:Humans; D011634:Public Health; D018088:Tuberculosis, Multidrug-Resistant / Q000191:economics*